Frontline Lenalidomide for AL Amyloidosis Involving Myocardium

PHASE3CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 20, 2019

Primary Completion Date

November 25, 2021

Study Completion Date

November 25, 2021

Conditions
Amyloidosis Cardiac
Interventions
DRUG

Lenalidomide 25mg

"As single arm study, patients will be treated as follows:~* Lenalidomide : D1\~D21 daily oral administration, starting dose 15mg, with an increase of 5mg every cycle, if tolerated, up to 25mg.~* Dexamethasone : D1\~D4 daily oral administration or intravenous injection, 40mg(or 20mg for age for age ≥ 65 years old) Patients will be treated every 4 weeks as one cycle, and up to 12 cycles of treatment will be conducted."

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT04298372 - Frontline Lenalidomide for AL Amyloidosis Involving Myocardium | Biotech Hunter | Biotech Hunter